Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Liabilities and Shareholders Equity (2016 - 2026)

Champions Oncology has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $28.4 million for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity fell 7.12% year-over-year to $28.4 million; the TTM value through Jan 2026 reached $121.5 million, up 13.62%, while the annual FY2025 figure was $32.3 million, 23.77% up from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 was $28.4 million at Champions Oncology, down from $30.2 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $36.4 million in Q4 2022 and troughed at $24.9 million in Q3 2024.
  • A 5-year average of $30.8 million and a median of $30.5 million in 2025 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 32.95% in 2022 and later fell 25.9% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $36.4 million in 2022, then fell by 22.19% to $28.3 million in 2023, then dropped by 10.79% to $25.2 million in 2024, then grew by 19.5% to $30.2 million in 2025, then decreased by 5.69% to $28.4 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for CSBR at $28.4 million in Q1 2026, $30.2 million in Q4 2025, and $30.5 million in Q3 2025.